Motor Neuron Diseases - Progressive Neurodegenerative Disorders

Clinical Spectrum of Motor Neuron Diseases (MND)

The clinical presentation of MNDs is highly heterogeneous, depending on the type and localization of the affected neurons:

1. Amyotrophic Lateral Sclerosis (ALS)

• • Muscle Weakness: Asymmetrical, initially focal, and relentlessly progressive.

  • Muscle Atrophy: Progressive and diffuse loss of muscle mass.

  • Fasciculations: Involuntary muscle twitches, both visible and palpable.

  • Spasticity: Hyperreflexia (overactive reflexes), clonus, and the Babinski sign.

  • Bulbar Symptoms: Dysarthria (difficulty articulating speech) and progressive dysphagia (difficulty swallowing).

  • Clinical Phenotypes: * Spinal onset (70%): Initially affecting the limbs.

    • Bulbar onset (25%): Initially affecting speech and swallowing.

    • Respiratory onset (5%): Rare, presenting with early breathing difficulties.

2. Spinal Muscular Atrophy (SMA)

• SMA Type 1: Onset 0–6 months; inability to sit independently; severe hypotonia (“floppy baby”).

• SMA Type 2: Onset 6–18 months; can sit but unable to walk independently.

• SMA Type 3: Onset >18 months; walking is achieved; slow progression.

• SMA Type 4: Adult onset; very slow progression.

3. SMARD1 (Spinal Muscular Atrophy with Respiratory Distress Type 1)

• Onset: 6 weeks to 6 months with early-onset respiratory distress.

• Weakness: Predominantly distal in the lower limbs.

• Key Feature: Rapid and severe respiratory failure.

4. Primary Lateral Sclerosis (PLS)

• Involvement: Selective upper motor neuron involvement; spasticity is the predominant feature.

• Symptoms: Stiffness (rigidity), dysarthria, and slow progression.

• Prognosis: Generally better than classic ALS, though evolution into ALS is possible.

5. Progressive Muscular Atrophy (PMA)

• Involvement: Selective lower motor neuron involvement.

• Symptoms: Weakness, atrophy, and fasciculations without spasticity.

• Diagnosis: Requires the exclusion of central (upper motor neuron) involvement.

6. Systemic Manifestations

• Respiratory: Exertional dyspnea progressing to dyspnea at rest; ineffective cough; nocturnal apnea.

• Cognitive: Preserved in most patients; ALS-FTD (5–15%) presents with Frontotemporal Dementia.

• Bulbar Functions: Sialorrhea (excessive drooling), emotional lability (pseudobulbar affect), and impairment of facial muscles.

Diagnostic Evaluation and Protocols for MND

The diagnostic process for Motor Neuron Diseases requires a multidisciplinary integration of clinical, electrophysiological, and molecular data:

1. Clinical Assessment

• Comprehensive Evaluation: Detailed family history and complete neurological examination.

• Physical Signs: Assessment of muscle strength, deep tendon reflexes, and pyramidal signs.

• Phenotyping: Identification of weakness patterns and temporal progression.

2. ALS Diagnostic Criteria (Revised El Escorial)

Diagnosis is based on the presence of Upper Motor Neuron (UMN) and Lower Motor Neuron (LMN) signs across anatomical regions:

• Definite ALS: Signs in 3 regions.

• Probable ALS: Signs in 2 regions.

• Possible ALS: Signs in 1 region.

3. Electrophysiology

• Electromyography (EMG): Detection of acute/chronic denervation, fasciculations, and reinnervation.

• Nerve Conduction Studies (NCS): Typically normal in pure motor neuron forms; used to rule out neuropathies.

• Advanced Metrics: Identification of giant potentials and reduction in motor unit estimates.

4. Genetic Diagnostics

• Testing: NGS (Next-Generation Sequencing) panels for MND-related genes.

• Indications: Positive family history, early-onset, or atypical clinical presentations.

• Key Genes: C9orf72, SOD1, TARDBP, FUS (for ALS); SMN1 (for SMA).

5. Specialized Imaging

• Brain MRI: Assessment of motor cortex atrophy and corticospinal tract alterations.

• Spinal MRI: Evaluation of cord atrophy and T2-hyperintensities.

• Structural Review: Mandatory to exclude structural lesions (e.g., tumors, spondylotic myelopathy).

6. Biomarkers

• Plasma/Serum: Neurofilament Light chain (NfL) as a core marker for disease progression.

• Cerebrospinal Fluid (CSF): Analysis of pTau, TDP-43, and inflammatory cytokines.

• Experimental: MicroRNA profiling for disease-specific signatures.

7. Differential Diagnosis (Exclusion Criteria)

• Myopathies: Ruled out by high Creatine Kinase (CK) levels and muscle biopsy.

• Neuropathies: Differentiated by distribution patterns and altered NCS.

• Neuromuscular Junction Disorders: Differentiated by pathological fatigability (e.g., Myasthenia Gravis).